Cognivue Clarity® characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study.

IF 3.4 3区 医学 Q2 NEUROSCIENCES Journal of Alzheimer's Disease Pub Date : 2025-01-26 DOI:10.1177/13872877251314117
James E Galvin, Michael J Kleiman, Paul W Estes, Heather M Harris, Ernest Fung
{"title":"Cognivue <i>Clarity</i><sup>®</sup> characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study.","authors":"James E Galvin, Michael J Kleiman, Paul W Estes, Heather M Harris, Ernest Fung","doi":"10.1177/13872877251314117","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cognivue <i>Clarity</i><sup>®</sup> is an FDA-cleared computerized cognitive test to screen for cognitive impairment included in the Bio-Hermes Study to test blood-based and digital biomarkers' ability to screen for mild cognitive impairment (MCI) and Alzheimer's disease (AD). A subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but no current assessment can identify these individuals in the absence of expensive biomarkers.</p><p><strong>Objective: </strong>We examined differences in Cognivue <i>Clarity</i> performance between amyloid positive and amyloid negative individuals and whether Cognivue <i>Clarity</i> could differentiate True Controls (cognitively normal/amyloid negative), Preclinical AD (cognitively normal/amyloid positive), and MCI due to AD (MCI-AD, cognitively impaired/amyloid positive).</p><p><strong>Methods: </strong>Cognivue <i>Clarity</i> was administered to all participants in the Bio-Hermes Study who also had amyloid PET and blood-based biomarkers. Performance was compared between biomarker-defined groups: True Controls (n = 297), Preclinical AD (n = 95), and MCI-AD (n = 113).</p><p><strong>Results: </strong>Cognivue <i>Clarity</i> global scores distinguished amyloid positive individuals from amyloid negative individuals (<i>p</i> < 0.001) and differentiated True Controls versus Preclinical AD (<i>p</i> = 0.014) and Preclinical AD versus MCI-AD (<i>p</i> < 0.001). Three subtests [Shape Discrimination (<i>p</i> = 0.004), Visual Salience (<i>p</i> = 0.008), Adaptive Motor Control (<i>p</i> = 0.004)] and the 3-test mean (<i>p</i> < 0.001) differentiated True Controls from Preclinical AD. The 3-test composite correlated with Amyloid PET (r = -0.433) and pTau217 (r = -0.400). The 3-test mean identified Preclinical AD in both White and Black participants.</p><p><strong>Conclusions: </strong>Cognivue <i>Clarity</i>, a 10-min computerized battery, screens for individuals with cognitive impairment, characterizes amyloid positive individuals, and identifies Preclinical AD. This has great potential as a cost- and time-effective strategy to screen and enroll in AD prevention trials.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251314117"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13872877251314117","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cognivue Clarity® is an FDA-cleared computerized cognitive test to screen for cognitive impairment included in the Bio-Hermes Study to test blood-based and digital biomarkers' ability to screen for mild cognitive impairment (MCI) and Alzheimer's disease (AD). A subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but no current assessment can identify these individuals in the absence of expensive biomarkers.

Objective: We examined differences in Cognivue Clarity performance between amyloid positive and amyloid negative individuals and whether Cognivue Clarity could differentiate True Controls (cognitively normal/amyloid negative), Preclinical AD (cognitively normal/amyloid positive), and MCI due to AD (MCI-AD, cognitively impaired/amyloid positive).

Methods: Cognivue Clarity was administered to all participants in the Bio-Hermes Study who also had amyloid PET and blood-based biomarkers. Performance was compared between biomarker-defined groups: True Controls (n = 297), Preclinical AD (n = 95), and MCI-AD (n = 113).

Results: Cognivue Clarity global scores distinguished amyloid positive individuals from amyloid negative individuals (p < 0.001) and differentiated True Controls versus Preclinical AD (p = 0.014) and Preclinical AD versus MCI-AD (p < 0.001). Three subtests [Shape Discrimination (p = 0.004), Visual Salience (p = 0.008), Adaptive Motor Control (p = 0.004)] and the 3-test mean (p < 0.001) differentiated True Controls from Preclinical AD. The 3-test composite correlated with Amyloid PET (r = -0.433) and pTau217 (r = -0.400). The 3-test mean identified Preclinical AD in both White and Black participants.

Conclusions: Cognivue Clarity, a 10-min computerized battery, screens for individuals with cognitive impairment, characterizes amyloid positive individuals, and identifies Preclinical AD. This has great potential as a cost- and time-effective strategy to screen and enroll in AD prevention trials.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Alzheimer's Disease
Journal of Alzheimer's Disease 医学-神经科学
CiteScore
6.40
自引率
7.50%
发文量
1327
审稿时长
2 months
期刊介绍: The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.
期刊最新文献
Adherence to intervention components: The key to success? Analysis on health-related outcomes of the AgeWell.de intervention to preserve cognition. Analysis of the causal relationship between five chosen factors and early-onset Alzheimer's disease: A Mendelian randomization study. Brain-penetrant histone deacetylase inhibitor RG2833 improves spatial memory in females of an Alzheimer's disease rat model. Clinical characteristics of semantic variant of primary progressive aphasia with TDP-43- and tau-related gene variants. Cognitive function instrument-based anosognosia to predict amyloid status.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1